Paakinaho V, Palvimo JJ (2021) Genome-wide crosstalk between steroid receptors in breast and prostate cancers. Endocr Relat Cancer 28(9):R231–R250

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swami U, McFarland TR, Nussenzveig R, Agarwal N (2020) Advanced prostate cancer: treatment advances and future directions. Trends Cancer 6(8):702–715

Article  CAS  PubMed  Google Scholar 

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I et al (2019) Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A 116(23):11428–11436

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carceles-Cordon M, Kelly WK, Gomella L, Knudsen KE, Rodriguez-Bravo V, Domingo-Domenech J (2020) Cellular rewiring in lethal prostate cancer: the architect of drug resistance. Nat Rev Urol 17(5):292–307

Article  PubMed  PubMed Central  Google Scholar 

Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D et al (2013) A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 3(9):1020–1029

Article  CAS  PubMed  Google Scholar 

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028–1038

Article  PubMed  PubMed Central  Google Scholar 

Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD et al (2013) XGlucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 155(6):1309–1322

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalfeist L, Galland L, Ledys F, Ghiringhelli F, Limagne E, Ladoire S (2022) Impact of glucocorticoid use in oncology in the immunotherapy era. Cells. 11(5):770

Article  CAS  PubMed  PubMed Central  Google Scholar 

Serritella AV, Shevrin D, Heath EI, Wade JL, Martinez E, Anderson A et al (2022) Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer. Clin Cancer Res 28(8):1549–1559

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang J, Yuan J, Hu Z, Xu M, Zhang Y, Long M et al (2022) Systematic pan-cancer characterization of nuclear receptors identifies potential cancer biomarkers and therapeutic targets. Cancer Res 82(1):46–59

Article  CAS  PubMed  Google Scholar 

Burris TP, de Vera IMS, Cote I, Flaveny CA, Wanninayake US, Chatterjee A et al (2023) International union of basic and clinical pharmacology cxiii: nuclear receptor superfamily-update 2023. Pharmacol Rev 75(6):1233–1318

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lempiäinen JK, Niskanen EA, Vuoti KM, Lampinen RE, Göös H, Varjosalo M et al (2017) Agonist-specific protein interactomes of glucocorticoid and androgen receptor as revealed by proximity mapping. Mol Cell Proteomics 16(8):1462–1474

Article  PubMed  PubMed Central  Google Scholar 

Valencia AM, Kadoch C (2019) Chromatin regulatory mechanisms and therapeutic opportunities in cancer. Nat Cell Biol 21(2):152–161

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jafari H, Hussain S, Campbell MJ (2022) Nuclear receptor coregulators in hormone-dependent cancers. Cancers (Basel). 14(10):2402

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bates SE (2020) Epigenetic therapies for cancer. N Engl J Med 383(7):650–663

Article  CAS  PubMed  Google Scholar 

Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL et al (2017) Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature 550(7674):128–132

Article  CAS  PubMed  PubMed Central  Google Scholar 

Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand SN et al (2021) Targeting the p300/cbp axis in lethal prostate cancer. Cancer Discov 11(5):1118–1137

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87(5):953–959

Article  CAS  PubMed  Google Scholar 

Vo N, Goodman RH (2001) CREB-binding protein and p300 in transcriptional regulation. J Biol Chem 276(17):13505–13508

Article  CAS  PubMed  Google Scholar 

Comuzzi B, Nemes C, Schmidt S, Jasarevic Z, Lodde M, Pycha A et al (2004) The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 204(2):159–166

Article  CAS  PubMed  Google Scholar 

Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DAL, Tindall DJ (2003) p300 in prostate cancer proliferation and progression. Cancer Res 63(22):7638–7640

CAS  PubMed  Google Scholar 

Millán-Zambrano G, Burton A, Bannister AJ, Schneider R (2022) Histone post-translational modifications - cause and consequence of genome function. Nat Rev Genet 23(9):563–580

Article  PubMed  Google Scholar 

Zucconi BE, Makofske JL, Meyers DJ, Hwang Y, Wu M, Kuroda MI et al (2019) Combination targeting of the bromodomain and acetyltransferase active site of p300/CBP. Biochemistry 58(16):2133–2143

Article  CAS  PubMed  Google Scholar 

Weinert BT, Narita T, Satpathy S, Srinivasan B, Hansen BK, Schölz C et al (2018) Time-resolved analysis reveals rapid dynamics and broad scope of the CBP/p300 acetylome. Cell 174(1):231-244.e12

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kikuchi M, Morita S, Wakamori M, Sato S, Uchikubo-Kamo T, Suzuki T et al (2023) Epigenetic mechanisms to propagate histone acetylation by p300/CBP. Nat Commun 14(1):4103

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wimalasena VK, Wang T, Sigua LH, Durbin AD, Qi J (2020) Using chemical epigenetics to target cancer. Mol Cell 78(6):1086–1095

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu X, Yi P, Hamilton RA, Shen H, Chen M, Foulds CE et al (2020) Structural insights of transcriptionally active, full-length androgen receptor coactivator complexes. Mol Cell 79(5):812-823.e4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Furlan T, Kirchmair A, Sampson N, Puhr M, Gruber M, Trajanoski Z et al (2021) MYC-mediated ribosomal gene expression sensitizes enzalutamide-resistant prostate cancer cellS TO EP300/CREBBP inhibitors. Am J Pathol 191(6):1094–1107

Article  CAS  PubMed  Google Scholar 

Helminen L, Huttunen J, Tulonen M, Aaltonen N, Niskanen EA, Palvimo JJ et al (2024) Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer. Nucleic Acids Res 52(2):625–642

Article  PubMed  Google Scholar 

McDowell IC, Barrera A, D’Ippolito AM, Vockley CM, Hong LK, Leichter SM et al (2018) Glucocorticoid receptor recruits to enhancers and drives activation by motif-directed binding. Genome Res 28(9):1272–1284

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karvonen U, Kallio PJ, Jänne OA, Palvimo JJ (1997) Interaction of androgen receptors with androgen response element in intact cells. Roles of amino- and carboxyl-terminal regions and the ligand. J Biol Chem. 272(25):15973–15979

Article  CAS  PubMed  Google Scholar 

Launonen KM, Paakinaho V, Sigismondo G, Malinen M, Sironen R, Hartikainen JM et al (2021) Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells. Oncogene 40(27):4567–4579

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S et al (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29(1):15–21

Article  CAS  PubMed  Google Scholar 

Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550

Article  PubMed  PubMed Central  Google Scholar